Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Abbott 2Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Abbott 2Q

Worldwide pharmaceutical sales were $3.9 billion (-4%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abbott 2Q

2Q Revenues: $7.5 billion (+3%)

2Q Earnings: $1.3 billion (-3%)

YTD Revenues: $14.2 billion (+1%)

YTD Earnings: $2.7 billion (+21%)

Comments: Worldwide pharmaceutical sales were $3.9 billion (-4%).
Depakote sales were down 75% to $102 million due to generic competition. Humira sales were $1.3 billion (+20%). Kaletra sales were $343 million (-4%). TriCor/Trilipix sales were $336 million (+9%). Lupron sales were up 28% to $197 million. Worldwide vascular sales were $658 million (+34%), with U.S. vascular sales up 81% to $395 million. Earnings include a $505 million after-tax gain and ongoing contractual payments from Takeda associated with the conclusion of the TAP joint venture.

Sign up today for Contracting & Outsourcing 2009!
stagging_cp.rodpub.com/2009conference

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters